Drug Search Results
More Filters [+]

Bimosiamose

Alternative Names: bimosiamose
Latest Update: 2023-03-01
Latest Update Note: PubMed Publication

Product Description

an inhaled small-molecule pan-selectin antagonist (Sourced from: https://pubmed.ncbi.nlm.nih.gov/16140027/)

Mechanisms of Action: P-selectin Antagonist

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Topical

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Revotar
Company Location:
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Bimosiamose

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 2: Chronic Obstructive Pulmonary Disease|Psoriasis|Healthy Volunteers

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

2006-7041-83/hah

N/A

Not yet recruiting

Stress Disorders, Post-Traumatic

2020-06-29

2009-017257-35

P2

Completed

Chronic Obstructive Pulmonary Disease

2010-12-17

2009-013163-18

P2

Completed

Healthy Volunteers

2009-12-17

Psoriasis POC

P2

Completed

Psoriasis

2009-08-20

Recent News Events